Drug Trial Radar · NCT07617532
Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma
Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Ache Laboratorios Farmaceuticos S.A.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.
Conditions
- Ocular Hypertension
- Primary Open Angle Glaucoma
Interventions
Product DNN.31.19.026Drug
One drop in the affected eye twice daily
COSOPT®Drug
One drop in the affected eye twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in diurnal intraocular pressure (IOP)Time frame: 56 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.